Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Dupixent“
Suchtreffer
Begriffe & Kennungen
Dupixent · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenDupixent · 4.6 Fertility, pregnancy and lactation · 2
Eintrag öffnenDupixent · 4.8 Undesirable effects · 1
Eintrag öffnenDupixent · 4.8 Undesirable effects · 2
Eintrag öffnenDupixent · 4.8 · 10 Listed in Table 8 are adverse reactions observed in clinical trials and/or postmarketing setting presented
Eintrag öffnenDupixent · 4.8 · 11 Eczema herpeticum Eczema herpeticum was reported in < 1% of the dupilumab groups and in < 1 % of the placeb
Eintrag öffnenDupixent · 4.8 · 12 respiratory tract infection was numerically higher with dupilumab (17.2%) compared to placebo (10.3%) in Eo
Eintrag öffnenDupixent · 4.8 · 13 Less than 1 % of patients who received dupilumab at approved dosing regimens exhibited high titer ADA respo
Eintrag öffnenDupixent · 4.8 · 14 The long-term safety of dupilumab was assessed in an open-label extension study (EXCURSION) in children 6 t
Eintrag öffnenDupixent · 4.8 · 15 Asthma The safety profile of dupilumab in the 96 weeks long term safety study (TRAVERSE) was consistent wit
Eintrag öffnenDupixent · 4.8 · 72 rare (< 1/10 000); not known (cannot be estimated from the available data). Within each frequency grouping,
Eintrag öffnenDupixent · 4.8 · 73 group and 1.9 % of the placebo + TCS group. These rates remained stable at 5 years in the long-term OLE stu
Eintrag öffnenDupixent · 4.8 · 74 In the safety pool for CUPID studies (A, B, and C) no increase was observed in the overall incidence of inf
Eintrag öffnenDupixent · 4.8 · 75 Atopic dermatitis
Eintrag öffnenDupixent · 4.8 · 76 The long-term safety profile of dupilumab in EXCURSION was consistent with the safety profile observed in t
Eintrag öffnenDupixent · 4.8 · 77 The safety profile of dupilumab in the 96 weeks long term safety study (TRAVERSE) was consistent with the s
Eintrag öffnenDupixent · 4.8 · A total of 99 adolescents aged 12 to 17 years with EoE were enrolled in the TREET (Parts A and B) studies. The
Eintrag öffnenDupixent · 4.8 · A total of 99 adolescents aged 12 to 17 years with EoE were enrolled in the TREET (Parts A and B) studies. The
Eintrag öffnenDupixent · 4.8 · Adolescents (12 t o17 years of age) A total of 107 adolescents aged 12 to 17 years with asthma were enrolled i
Eintrag öffnenDupixent · 4.8 · Adolescents (12 t o17 years of age) The safety of dupilumab was assessed in a study of 250 patients 12 to 17 y
Eintrag öffnen